Skip to main content
SpringerLink
Log in

Is it ethical to use placebos in osteoporosis clinical trials?

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Because there are now effective agents for treatment of osteoporosis, the question is being raised as to whether or not it is ethical to have placebo-controlled trials of new agents. It is ethical for patients who are at low risk of serious or irreversible harm to participate in placebo-controlled trials as long as they provide informed consent. Morbidity, mortality, and future fracture risk correlate with the presence of previous fractures, the number of previous fractures, whether or not the fracture is recent, and whether or not the fracture is clinically recognized. Lower-risk subjects who may be allowed to participate in placebo-controlled trials include those with low bone density but without a previous vertebral fracture, those with a single vertebral deformity that was not clinically recognized, and those with a vertebral fracture more than 2 years before. Higher-risk subjects who do not tolerate proven drugs or who have not responded to proven drugs may also participate. Even though it may be ethical for selected subjects to participate in placebo-controlled trials of new therapies for osteoporosis, steps should be taken to minimize their exposure (eg, unbalanced randomization, integration of outcomes, and powering trials to actual events rather than a projected number over 3 years), and treating patients who fracture or who fail to respond.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Capron A, Donaldson S, Raisz LG, Swift S: Osteoporosis panel summary. J Bone Miner Res 2003, 18:1160–1162.

    Article  PubMed  Google Scholar 

  2. Temple R, Ellenberg SS: Placebo-controlled trials and activecontrol trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 2000, 133:455–463. A good discussion of ethical and scientific issues surrounding clinical trials.

    PubMed  CAS  Google Scholar 

  3. Ellenberg SS, Temple R: Placebo-controlled trials and activecontrol trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 2000, 133:464–470. A good discussion of practical issues of clinical trials.

    PubMed  CAS  Google Scholar 

  4. Guidelines for preclinical and clinical evaluation of agents in the prevention or treatment of postmenopausal osteoporosis. Available at http://www.fda.gov/cder/guidance/osteo.pdf.

  5. Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis Geneva, Switzerland: World Health Organization; 1998.

  6. European Agency for the Evaluation of Medicinal Production, Committee for Proprietary Medicinal Products CPMP: Note for guidance on postmenopausal osteoporosis in women. Available at http://www.emea.eu.int/pdfs/human/ewp/055295en.pdf.

  7. World Medical Association: Declaration of Helsinki. Available at http://www.wma.net/e/policy/b3.htm. This is the "Declaration of Helsinki." Article 29 sets forth the position of the World Medical Association on clinical trials.

  8. Recker RR, Hinders S, Davies KM, et al.: Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 1996, 11:1961–1966.

    Article  PubMed  CAS  Google Scholar 

  9. Dawson-Hughes B, Harris SS, Krall EA, Dallal G: Effects of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med 1997, 337:670–676.

    Article  PubMed  CAS  Google Scholar 

  10. Black DM, Cummings SR, Karpf DB, et al.: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535–1541.

    Article  PubMed  CAS  Google Scholar 

  11. Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999, 282:637–645.

    Article  PubMed  CAS  Google Scholar 

  12. Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999, 282:1344–1352.

    Article  PubMed  CAS  Google Scholar 

  13. Chesnut CH, III, Silverman S, Andriano K, et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000, 102:267–276.

    Article  Google Scholar 

  14. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441.

    Article  PubMed  CAS  Google Scholar 

  15. Cummings SR, Black DM, Thompson DE, et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077–2082.

    Article  PubMed  CAS  Google Scholar 

  16. Reginster JY, Minne HW, Sorensen OH, et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000, 11:83–91.

    Article  PubMed  CAS  Google Scholar 

  17. Ross PD, Davis JW, Epstein RS, Wasnich RD: Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991, 114:919–923.

    PubMed  CAS  Google Scholar 

  18. Lindsay R, Silverman SL, Cooper C, et al.: Risk of new vertebral fracture in the year following a fracture. JAMA 2001, 285:320–323.

    Article  PubMed  CAS  Google Scholar 

  19. Cummings SR, Modelska K, Nevitt MC, Black DM: Are placebo-controlled trials ethical for women with osteoporosis [abstract]? J Bone Miner Res 2001, 16(suppl):S220.

    Google Scholar 

  20. Nevitt MC, Ettinger B, Black DM, et al.: The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998, 128:793–800.

    PubMed  CAS  Google Scholar 

  21. Silverman SL, Minshall ME, Shen W, et al.: The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the multiple outcomes of raloxifene evaluation study. Arthritis Rheum 2001, 44:2611–2619.

    Article  PubMed  CAS  Google Scholar 

  22. Cooper C, Atkinson EJ, Jacobsen SJ, et al.: Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993, 137:1001–1005.

    PubMed  CAS  Google Scholar 

  23. Kado DM, Browner WS, Palermo L, et al.: Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999, 159:1215–1220.

    Article  PubMed  CAS  Google Scholar 

  24. Sarkar S, Mitlak BH, Wong MM, et al.: Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002, 17:1–10.

    Article  PubMed  CAS  Google Scholar 

  25. Bjarnason NH, Sarkar S, Duong T, et al.: Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001, 12:922–30.

    Article  PubMed  CAS  Google Scholar 

  26. Eastell R, Barton I, Hannon RA, et al.: Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18:1051–1056.

    Article  PubMed  CAS  Google Scholar 

  27. Cleophas TJ, Zwinderman AH: Limitations of randomized clinical trials: proposed alternative designs. Clin Chem Lab Med 2000, 38:1217–1223. An excellent discussion of design issues in clinical trials.

    Article  PubMed  CAS  Google Scholar 

  28. Rosner F: The ethics of randomized clinical trials. Am J Med 1987, 82:283–290.

    Article  PubMed  CAS  Google Scholar 

  29. Watts NB, Lindsay R, Li Z, et al.: Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 2003, 437–441. An example of the use of historical control subjects to evaluate antifracture efficacy in a study in which there was no simultaneous placebo group.

  30. Dowd R, Recker RR, Heaney RP: Study subjects and ordinary patients. Osteoporos Int 2000, 11:533–536.

    Article  PubMed  CAS  Google Scholar 

  31. Chesnut CH, III: Osteoporosis: an under-diagnosed disease. JAMA 2001, 286:2865–2866.

    Article  PubMed  Google Scholar 

  32. Gehlbach SH, Bigelow C, Heimisdottir M, et al.: Recognition of vertebral fracture in a clinical setting. Osteoporos Int 2000, 11:577–582.

    Article  PubMed  CAS  Google Scholar 

  33. Kiebzak GM, Beinart GA, Perser K, et al.: Under-treatment of osteoporosis in men with hip fracture. Arch Intern Med 2002, 162:2217–2222.

    Article  PubMed  Google Scholar 

  34. Kanis JA, Oden A, Johnell O, et al.: Uncertain future of trials in osteoporosis. Osteoporos Int 2002, 13:443–449. A superb exposition of problems with superiority and non-inferiority trials and the sample size needed for various types of studies.

    Article  PubMed  CAS  Google Scholar 

  35. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research: The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: US Government Printing Office; 1979.

    Google Scholar 

  36. Russell-Einhorn M, Ellis GB: Human subject protections in the United States: perspectives from the Office for Protection from Research Risks. J Biolaw Bus 1998, 1:36–38.

    PubMed  CAS  Google Scholar 

  37. Holmes-Rovner M, Wills CE: Improving informed consent: insights from behavioral decision research. Med Care 2002, 40:308.

    Article  Google Scholar 

  38. O’Neill O: Some limits of informed consent. J Med Ethics 2003, 29:4–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Health and Osteoporosis Center, University of Cincinnati College of Medicine, 222 Piedmont Avenue, Suite 4300, 45219, Cincinnati, OH, USA

    Nelson B. Watts MD

Authors
  1. Nelson B. Watts MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Watts, N.B. Is it ethical to use placebos in osteoporosis clinical trials?. Curr Rheumatol Rep 6, 79–84 (2004). https://doi.org/10.1007/s11926-004-0087-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-004-0087-z

Keywords

Search

Navigation